Longeveron Reports Q2 2026 Financial Results and Provides Clinical Update
Longeveron (LGVN) reported a net loss of $6.1 million for the second quarter of 2026, reflecting a 22% increase due to higher general, administrative, and clinical trial expenses. Total revenue was $0.3 million, down 10% year-over-year primarily because of the absence of contract manufacturing income. The company ended Q2 with cash and equivalents totaling $10.1 million, which management expects will fund operations through the fourth quarter of 2026. The firm highlighted its Hypoplastic Left Heart Syndrome (HLHS) program as a key focus area, with top-line results from the ELPIS II trial expected in September 2026. Longeveron also received $1 million for being selected as an XPRIZE Healthspan Milestone 2 finalist and is eligible to compete for up to $81 million in that competition through 2029. The company holds a robust patent portfolio of 52 issued patents globally, supporting its mesenchymal stem cell therapy laromestrocel.
